Related Experiment Video
Updated: Apr 28, 2026

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
Published on: May 16, 2012
MicroRNAs in testicular cancer: implications for pathogenesis, diagnosis, prognosis and therapy
Angelika Bezan1, Armin Gerger1, Martin Pichler2
1Division of Clinical Oncology, Medical University of Graz, Comprehensive Cancer Center Graz, Graz, Austria.
Abstract:
Testicular germ cell tumors (TGCTs) represent the most common type of solid tumors among men aged 15 to 40 years. An increasing incidence has been recorded in developed countries. In clinical practice, TGCTs are classified as seminomas and non-seminomatous tumors. Non-seminomatous tumors often contain multiple different cell types and can be further sub-divided according to the histological and cellular phenotype in embryonal carcinomas, choriocarcinomas, yolk sac tumors and teratomas. For the clinical management of TGCTs, blood-based markers such as lactate dehydrogenase, alpha-fetoprotein and human chorionic gonadotropin are essential tools for diagnosis, risk assessment and patient's prognosis. However, only 60% of patients with TGCTs show increased serum levels of these tumor markers. This proportion of patients is even lower for those with seminomas or pure embryonal carcinomas as alpha-fetoprotein is predominantly related to yolk sac tumor and human chorionic gonadotropin to choriocarcinoma.
Insights
Testicular germ cell tumors (TGCTs) are common in young men. Current blood tumor markers are not always elevated in TGCT patients, limiting their diagnostic utility.
Area of Science:
- Oncology
- Urology
Background:
- Testicular germ cell tumors (TGCTs) are the most frequent solid tumors in men aged 15-40.
- TGCT incidence is rising in developed nations.
- TGCTs are categorized into seminomas and non-seminomatous tumors, with the latter further classified by histology.
Purpose of the Study:
- To highlight the importance of blood-based tumor markers in TGCT management.
- To address the limitations of current tumor markers in diagnosing TGCTs.
Main Methods:
- Review of clinical classification of TGCTs.
- Discussion of commonly used blood tumor markers: lactate dehydrogenase (LDH), alpha-fetoprotein (AFP), and human chorionic gonadotropin (hCG).
Main Results:
- Current tumor markers (LDH, AFP, hCG) are crucial for TGCT diagnosis, risk assessment, and prognosis.
- Approximately 40% of TGCT patients do not exhibit elevated serum levels of these markers.
- AFP and hCG levels are specifically linked to yolk sac tumors and choriocarcinomas, respectively, showing lower detection rates in seminomas and pure embryonal carcinomas.
Conclusions:
- The limited sensitivity of current tumor markers necessitates further research for improved diagnostic tools in TGCTs.
- Understanding marker specificities is vital for accurate interpretation in TGCT sub-types.
Related Concept Videos
MicroRNAs
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

